No profile data available.
Ginkgo Bioworks Holdings, Inc. (DNA) is a healthcare company in the laboratory analysis services industry, based in Boston, United States, with about 485 full-time employees.
It reported revenue of $227.04 million for fiscal year 2024, down 9.7% from fiscal year 2023, and net income of -$547.03 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $38.84 million, down 56.4% from a year before. Its largest business segment, Cell Engineering, brought in 78% of segment revenue in fiscal year 2025. Its market capitalization was $875.42 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments.
Ginkgo Bioworks reported $227.04 million in revenue for fiscal year 2024, down 9.7% from $251.46 million in fiscal year 2023. In Q3 2025 revenue was $38.84 million.
Cell Engineering, with $132.75 million or 78% of segment revenue in fiscal year 2025. Next: Biosecurity (22%).
$875.42 million as of October 9, 2026.
Listed companies of a similar size in the same industry (laboratory analysis services) include Personalis, Inc. (PSNL), Azenta, Inc. (AZTA), Dyadic International, Inc. (DYAI).